OCULAR THERAPEUTIX INC (OCUL) Fundamental Analysis & Valuation

NASDAQ:OCUL • US67576A1007

Current stock price

8.68 USD
+0.05 (+0.58%)
At close:
8.78 USD
+0.1 (+1.15%)
After Hours:

This OCUL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. OCUL Profitability Analysis

1.1 Basic Checks

  • In the past year OCUL has reported negative net income.
  • In the past year OCUL has reported a negative cash flow from operations.
  • In the past 5 years OCUL always reported negative net income.
  • In the past 5 years OCUL always reported negative operating cash flow.
OCUL Yearly Net Income VS EBIT VS OCF VS FCFOCUL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • OCUL has a Return On Assets (-32.91%) which is in line with its industry peers.
  • OCUL has a Return On Equity (-40.64%) which is in line with its industry peers.
Industry RankSector Rank
ROA -32.91%
ROE -40.64%
ROIC N/A
ROA(3y)-35.73%
ROA(5y)-31.6%
ROE(3y)-63.53%
ROE(5y)-79.74%
ROIC(3y)N/A
ROIC(5y)N/A
OCUL Yearly ROA, ROE, ROICOCUL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K 2K

1.3 Margins

  • OCUL's Gross Margin of 87.35% is amongst the best of the industry. OCUL outperforms 91.15% of its industry peers.
  • In the last couple of years the Gross Margin of OCUL has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for OCUL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.42%
GM growth 5Y-0.16%
OCUL Yearly Profit, Operating, Gross MarginsOCUL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. OCUL Health Analysis

2.1 Basic Checks

  • OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for OCUL has been increased compared to 1 year ago.
  • The number of shares outstanding for OCUL has been increased compared to 5 years ago.
  • The debt/assets ratio for OCUL has been reduced compared to a year ago.
OCUL Yearly Shares OutstandingOCUL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
OCUL Yearly Total Debt VS Total AssetsOCUL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 5.37 indicates that OCUL is not in any danger for bankruptcy at the moment.
  • OCUL's Altman-Z score of 5.37 is fine compared to the rest of the industry. OCUL outperforms 77.60% of its industry peers.
  • A Debt/Equity ratio of 0.11 indicates that OCUL is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.11, OCUL perfoms like the industry average, outperforming 51.04% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 5.37
ROIC/WACCN/A
WACC9.55%
OCUL Yearly LT Debt VS Equity VS FCFOCUL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 15.39 indicates that OCUL has no problem at all paying its short term obligations.
  • OCUL has a better Current ratio (15.39) than 86.98% of its industry peers.
  • OCUL has a Quick Ratio of 15.32. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 15.32, OCUL belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.39
Quick Ratio 15.32
OCUL Yearly Current Assets VS Current LiabilitesOCUL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. OCUL Growth Analysis

3.1 Past

  • OCUL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.04%.
  • OCUL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.47%.
  • Measured over the past years, OCUL shows a very strong growth in Revenue. The Revenue has been growing by 24.45% on average per year.
EPS 1Y (TTM)2.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y0.3%
Revenue growth 5Y24.45%
Sales Q2Q%-22.44%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.94% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 76.93% on average over the next years. This is a very strong growth
EPS Next Y5.48%
EPS Next 2Y6.63%
EPS Next 3Y5.62%
EPS Next 5Y26.94%
Revenue Next Year1.65%
Revenue Next 2Y40.03%
Revenue Next 3Y76.14%
Revenue Next 5Y76.93%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OCUL Yearly Revenue VS EstimatesOCUL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
OCUL Yearly EPS VS EstimatesOCUL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. OCUL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OCUL. In the last year negative earnings were reported.
  • Also next year OCUL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUL Price Earnings VS Forward Price EarningsOCUL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUL Per share dataOCUL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.63%
EPS Next 3Y5.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OCUL Dividend Analysis

5.1 Amount

  • OCUL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OCUL Fundamentals: All Metrics, Ratios and Statistics

OCULAR THERAPEUTIX INC

NASDAQ:OCUL (3/17/2026, 8:00:02 PM)

After market: 8.78 +0.1 (+1.15%)

8.68

+0.05 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)05-04
Inst Owners89.6%
Inst Owner Change-0.36%
Ins Owners2.29%
Ins Owner Change3.89%
Market Cap1.89B
Revenue(TTM)51.95M
Net Income(TTM)-265.94M
Analysts86.32
Price Target25.5 (193.78%)
Short Float %8.38%
Short Ratio2.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.55%
Min EPS beat(2)-1.62%
Max EPS beat(2)12.73%
EPS beat(4)1
Avg EPS beat(4)-5.84%
Min EPS beat(4)-26.63%
Max EPS beat(4)12.73%
EPS beat(8)2
Avg EPS beat(8)-37.37%
EPS beat(12)4
Avg EPS beat(12)-24.95%
EPS beat(16)6
Avg EPS beat(16)-17.93%
Revenue beat(2)0
Avg Revenue beat(2)-10.99%
Min Revenue beat(2)-19.46%
Max Revenue beat(2)-2.51%
Revenue beat(4)0
Avg Revenue beat(4)-15.02%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)-0.44%
Revenue beat(8)1
Avg Revenue beat(8)-9.84%
Revenue beat(12)2
Avg Revenue beat(12)-7.89%
Revenue beat(16)3
Avg Revenue beat(16)-8.44%
PT rev (1m)2.74%
PT rev (3m)11.94%
EPS NQ rev (1m)0.7%
EPS NQ rev (3m)7.22%
EPS NY rev (1m)6.78%
EPS NY rev (3m)2.7%
Revenue NQ rev (1m)-2.83%
Revenue NQ rev (3m)-12.55%
Revenue NY rev (1m)-9.2%
Revenue NY rev (3m)-11.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.37
P/FCF N/A
P/OCF N/A
P/B 2.89
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.24
BVpS3.01
TBVpS3.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.91%
ROE -40.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.35%
FCFM N/A
ROA(3y)-35.73%
ROA(5y)-31.6%
ROE(3y)-63.53%
ROE(5y)-79.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.42%
GM growth 5Y-0.16%
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 277.82%
Cap/Sales 23.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.39
Quick Ratio 15.32
Altman-Z 5.37
F-Score4
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)171.96%
Cap/Depr(5y)148.27%
Cap/Sales(3y)11.85%
Cap/Sales(5y)9.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y5.48%
EPS Next 2Y6.63%
EPS Next 3Y5.62%
EPS Next 5Y26.94%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y0.3%
Revenue growth 5Y24.45%
Sales Q2Q%-22.44%
Revenue Next Year1.65%
Revenue Next 2Y40.03%
Revenue Next 3Y76.14%
Revenue Next 5Y76.93%
EBIT growth 1Y-57.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.94%
EBIT Next 3Y29.09%
EBIT Next 5Y32.32%
FCF growth 1Y-59.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.13%
OCF growth 3YN/A
OCF growth 5YN/A

OCULAR THERAPEUTIX INC / OCUL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?

ChartMill assigns a fundamental rating of 4 / 10 to OCUL.


Can you provide the valuation status for OCULAR THERAPEUTIX INC?

ChartMill assigns a valuation rating of 0 / 10 to OCULAR THERAPEUTIX INC (OCUL). This can be considered as Overvalued.


How profitable is OCULAR THERAPEUTIX INC (OCUL) stock?

OCULAR THERAPEUTIX INC (OCUL) has a profitability rating of 2 / 10.


What is the earnings growth outlook for OCULAR THERAPEUTIX INC?

The Earnings per Share (EPS) of OCULAR THERAPEUTIX INC (OCUL) is expected to grow by 5.48% in the next year.